MIRM
Mirum Pharmaceuticals, Inc.
Next earnings Aug 4, 2026 (after close) · consensus $-0.70 EPS, $168M rev
Last earnings +4.0% on 2026-05-06
$123.77
▲ +5.53%$123.77▲ +146.19%
over 1Y
L $48.39EODHDH $123.77
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.5%
1W+14.8%
1M+27.2%
3M+39.9%
YTD+58.5%
1Y+146.2%
Buy
Conviction
Horizon
Long (>12mo)
12-mo target
$•••
Street · 19 analysts
Strong Buy
Rare-disease pharma scaling fast — revenue +54.7% to $521M, near breakeven, cash-flow positive — growth nearing the profitability inflection.
Revenue $521M · FY2025
Mirum Pharmaceuticals is a commercial-stage rare-disease company whose revenue ramp is the standout here — and unlike a typical pre-revenue biotech, it has approved, selling products. FY2025 revenue grew 54.7% to $521M, the latest leg of a remarkable trajectory from just $19.1M in FY2021 (through $77.1M, $186M and $337M). Crucially, the company is approaching profitability: net loss narrowed dramatically to -$23.4M from -$87.9M, operating loss shrank to -$22.1M, and operating cash flow swung firmly positive to $55.8M (+440.7%). That is the signature of a specialty-pharma model reaching scale, where commercial revenue is starting to cover the fixed cost base.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $19.1M | $77.1M | $186M | $337M | $521M |
| Gross profit | — | — | — | — | — |
| Operating income | -$173M | -$131M | -$109M | -$87.6M | -$22.1M |
| Net income | -$84.0M | -$136M | -$163M | -$87.9M | -$23.4M |
| Diluted EPS | -$2.77 | -$4.02 | -$4.00 | -$1.85 | -$0.47 |
| Net margin | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$7.17B
EV / EBITDA3402.2
EV / Sales13.8
EV / FCF130.7
P / FCF136.1
PEG (trailing)—
Earnings yield-0.3%
FCF yield0.7%
Quality & risk
ROIC (est.)-5.6%
Free cash flow$54.9M
Total debt—
Net cash$297M
Altman Z-Score8.40 safe
Piotroski F-Score4/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+23.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-172026-06-18open ↗8-KPeriod ending 2026-06-152026-06-18open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗144Filing2026-06-17open ↗4Period ending 2026-06-082026-06-09open ↗
Frequently asked
- Is Mirum Pharmaceuticals, Inc. (MIRM) a buy?
- MIRM currently carries a Buy rating with 3/5 conviction, derived from its latest SEC filings. Rare-disease pharma scaling fast — revenue +54.7% to $521M, near breakeven, cash-flow positive — growth nearing the profitability inflection.
- What is Mirum Pharmaceuticals, Inc.'s quality score?
- MIRM scores 50.45098039215686/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001759425, latest 10-Q filed 2026-05-06) · EODHD · analysis by claude-code · as of 6/21/2026, 8:56:37 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.